Health chiefs have sounded the alarm over a "concerning jump" in hard-to-treat gonorrhoea cases, with more occurring in 2025 than all of last year. Fresh stats unveiled by UK Health Security Agency ...

Ceftriaxone should not be used by patients with allergy to ceftriaxone or other cephalosporin class antibacterials, penicillins, or other beta-lactam antibacterials. Drug Name : Ceftriaxone ...

Public health officials have warned of a ‘concerning acceleration’ in cases of antibiotic-resistant gonorrhoea in England.

Ceftriaxone is an important agent for clinical use in meningitis, severe community-acquired pneumonia, and intraabdominal infection. It has no need for adjustment in renal dysfunction, ...

A new study published in The Lancet journal showed that Gepotidacin was non-inferior to the standard treatment of ceftriaxone ...

MONDAY, April 21, 2025 (HealthDay News) -- For uncomplicated urogenital gonorrhea, gepotidacin, which inhibits bacterial DNA replication, is noninferior to ceftriaxone plus azithromycin, according ...

New data from the UK Health Security Agency (UKHSA) reveals that the number of cases of the sexually transmitted infection (STI) gonorrhoea, which are resistant to the antibiotic ceftriaxone, has ...

One dose of ceftriaxone lowered the risk for ventilator-associated pneumonia within the first week of mechanical ventilation among patients with acute brain injury, according to results published ...

Standard treatment involves an injection of ceftriaxone, the last antibiotic that works against most N. gonorrhoeae strains, but some have evolved to resist this drug too, especially in Asia.

PHOENIX -- Administering ceftriaxone prophylactically in the intensive care unit (ICU) reduced the risk of ventilator-associated pneumonia (VAP) among patients with an acute brain injury, a ...

Concomitant Ceftriaxone and High-concentration Intravenous Calcium Therapy in Adult Critical Care Patients: A Matched Cohort Study. Bruce R Dalton, PharmD BScPharm; Danny J Zuege, ...

The microbiological intention-to-treat population included 406 participants (202 and 204 in the gepotidacin and ceftriaxone plus azithromycin groups, respectively).